Highly experienced leader with demonstrated track record of antibody-based drug discovery and pipeline advancement Strengthens Commit’s leadership team after emerging from stealth with €16m seed financing Dr Pedersen will spearhead research and development of Commit’s BiCETM technology as the Company moves towards drug candidate (DC) nomination Aarhus, Denmark, 15 October 2024 – Commit Biologics (“Commit”), […]
Financing led by Bioqube Ventures and Novo Holdings Commit is pioneering a novel approach to activating the complement component of the immune system to treat cancer and autoimmune diseases Its unique bispecific technology (BiCE™) engages the complement system, unleashing its power to selectively kill target cells Spin-out from Aarhus University in Denmark, a world leader […]
Invizius Limited (“Invizius”), a biotechnology company developing second generation therapies for a range of complement-driven autoimmune and inflammatory disorders, is pleased to announce that it has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to commence its First-in-Human clinical study of lead product, H-Guard. The study will be conducted at the […]
